Average Co-Inventor Count = 5.10
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Aventis Pharma S.a. (7 from 377 patents)
2. Aventis Pharmaceuticals Inc. (4 from 207 patents)
3. Rhone-poulenc Rorer S.a. (3 from 247 patents)
4. Institut National De La Sante Et De La Recherche Medicale (2 from 1,743 patents)
5. Aventis Pharmaceuticals Products Inc. (2 from 23 patents)
6. Other (1 from 832,680 patents)
7. Case Western Reserve University (1 from 1,306 patents)
8. Institut National Sante Et Recherche Medicale (1 from 1 patent)
18 patents:
1. 9540693 - Mutations of the parkin gene, compositions, methods and uses
2. 8835618 - Mutations of the parkin gene
3. 8642739 - Nuclear factor κB inducing factor
4. 8623831 - Nuclear factor κB inducing factor
5. 7998667 - Mutations of the parkin gene, compositions, methods and uses
6. 7972844 - Nuclear factor κB inducing factor
7. 7378274 - Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses
8. 7041497 - Nuclear factor κB inducing factor
9. 6893841 - Nucleic acids of the human ABCC11 gene, vectors containing such nucleic acids and uses thereof
10. 6814962 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
11. RE38556 - Recombinant adeno viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias
12. 6512161 - Transgenic rabbit that expresses a functional human lipoprotein (a)
13. 6410011 - Gene therapy for restenosis using an adenoviral vector
14. 6258596 - Variants of apolipoprotein A-I
15. 6033885 - Integrative recombinant adenoviruses, preparation thereof and